Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.
Jennifer le GuevelouColin DebaigtEsma Saada-BouzidJulien ViottiNazim KhalladiDavid ThibouwNicolas PenelMarie Pierre SunyachLaurence Moureau-ZabottoMohamed BenchalalOvidiu VeresezanAnne DucassouCecile le PechouxMaria JolnerovskiCeline BazilleDominique VaurAlexandre EscandeRaphael SerreChristine LoveraJuliette ThariatPublished in: BMJ open (2020)
This study has been approved by Comité de Protection des Personnes du sud-ouest et outre-mer 4 on 18 October 2019 (Reference CPP2019-09-076-PP) and from National Agency for Medical and Health products Safety (Reference: MEDAECNAT-2019-08-00004_2017-004239-35) on 18 September 2019.The results will be disseminated to patients upon individual request or through media release from scientific meetings. The results will be communicated through scientific meetings and publications.
Keyphrases
- phase ii study
- end stage renal disease
- healthcare
- locally advanced
- soft tissue
- ejection fraction
- chronic kidney disease
- newly diagnosed
- public health
- clinical trial
- open label
- randomized controlled trial
- early stage
- study protocol
- peritoneal dialysis
- mental health
- prognostic factors
- squamous cell carcinoma
- quality improvement
- phase iii
- radiation induced
- risk assessment
- drug administration
- rectal cancer
- social media
- human health
- climate change